[The effects of Ara-A on viral markers in duck hepatitis B virus carrier ducks].
Duck hepatitis B virus (DHBV) carrier ducks of one week old were injected with Ara-A (adenine arabinoside) of different dose including 2.5 (11 ducks), 5.0 (11), 10.0 (10) and 20.0 (10) mg/kg for 14 days. This antiviral effect showed dose-dependence up to 5.0 mg/kg and this dose seemed effective to obtain significant antiviral effect. Viral DNA and DNA polymerase activity were reduced significantly from the 1st week after starting the administration of Ara-A. This antiviral effect was maintained even at the 1st week after discontinuation of the drug. These findings were quite similar to those observed in HBV carriers. With the increasing necessity of Ara-A treatment in patients who will not respond to interferon therapy, DHBV seemed a suitable model for the investigation of the dose and antiviral effect of Ara-A treatment in humans.
Fukuda
R
R
2nd Department of Internal Medicine, Shimane Medical University.
Tokuda
A
A
Kohge
N
N
Xuan
N T
NT
Uchida
Y
Y
Akagi
S
S
Fukumoto
S
S
D000818:Animals; D002353:Carrier State / Q000188:drug therapy* / Q000382:microbiology; D004279:DNA, Viral / Q000032:analysis*; D004259:DNA-Directed DNA Polymerase / Q000032:analysis*; D004372:Ducks / Q000382:microbiology*; D018347:Hepadnaviridae Infections / Q000188:drug therapy* / Q000382:microbiology; D015611:Hepatitis B Virus, Duck / Q000187:drug effects* / Q000302:isolation & purification; D011201:Poultry Diseases / Q000188:drug therapy* / Q000382:microbiology; D014740:Vidarabine / Q000627:therapeutic use*
D004279:DNA, Viral; D004259:DNA-Directed DNA Polymerase; D014740:Vidarabine